Suppr超能文献

相似文献

9
Role of PDE4 in superoxide anion generation through p44/42MAPK regulation: a cAMP and a PKA-independent mechanism.
Br J Pharmacol. 2004 Sep;143(2):257-68. doi: 10.1038/sj.bjp.0705927. Epub 2004 Aug 16.
10
Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4.
Am J Respir Cell Mol Biol. 1998 Mar;18(3):411-20. doi: 10.1165/ajrcmb.18.3.2913.

引用本文的文献

2
Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19.
Pulm Pharmacol Ther. 2021 Feb;66:101978. doi: 10.1016/j.pupt.2020.101978. Epub 2020 Nov 28.
4
Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.
PLoS One. 2013 Sep 16;8(9):e74640. doi: 10.1371/journal.pone.0074640. eCollection 2013.
5
Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.
Br J Pharmacol. 2012 Mar;165(6):1877-1890. doi: 10.1111/j.1476-5381.2011.01667.x.
6
Airways disease: phenotyping heterogeneity using measures of airway inflammation.
Allergy Asthma Clin Immunol. 2007 Jun 15;3(2):60-9. doi: 10.1186/1710-1492-3-2-60.
7
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
Br J Pharmacol. 2010 Feb;159(4):842-55. doi: 10.1111/j.1476-5381.2009.00559.x. Epub 2009 Dec 24.
9
Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.
Biochem J. 2006 Jan 1;393(Pt 1):21-41. doi: 10.1042/BJ20051368.
10
Bench-to-bedside review: beta2-Agonists and the acute respiratory distress syndrome.
Crit Care. 2004 Feb;8(1):25-32. doi: 10.1186/cc2417. Epub 2003 Dec 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验